Planet Biotechnology Inc

Website Links

Description

Elliott Fineman, M.S., J.D., joined PLANET in 1998. He founded and served as Chief Operating Officer, Vice President and Director of Licensing and Intellectual Property of SuperGen, Incorporated , from January 1991 to August 1995. At SuperGen, he established facilities in Emeryville and Chicago, recruited the financial and operating management team, and assisted the CEO to develop overall company vision and strategy. He served as a general partner in two partnerships established to initially fund SuperGen's product development. He was instrumental in raising $15 million in early stage capital from private and corporate investors. In addition to Licensing and Intellectual Property responsibilities at SuperGen, he managed pre-clinical development for several products currently in clinical trials. He also contracted for sourcing several bulk drugs from China and Japan including doxorubicin, mitomycin C, daunorubicin, bleomycin, and paclitaxel and carried out GMP compliance audits for FDA approval in connection with Company ANDAs and INDs. From 1984 through 1991, Mr. Fineman held a series of positions of increasing responsibility at Cetus Corporation (later acquired by Chiron Corporation, Emeryville, CA) starting out as Senior Patent Attorney and ending as Director of Corporate Licensing. Prior to Cetus, he was a Senior Patent Attorney at Stauffer Chemical Company, with primary responsibility for agricultural biotechnology, and a patent Attorney in private practice. He holds a J.D. (1981) from the University of Baltimore where he served on the Law Review, an M.S. degree in Biology (1976) from Georgetown University where he was a University Fellow, and a BA with Honors in Biology (1972) from Oberlin College. Vice President and Chief Technical Officer: James W. Larrick, M.D. Ph.D. has an international reputation in biotechnology [cytokines, therapeutic antibodies, molecular biology, pharmaceutical drug development] having written or co-authored eight books, over 220 papers/chapters and fifteen patents. He serves on the editorial board of six journals. Dr. Larrick has worked on various aspects of therapeutic antibodies and other protein therapeutics for the past 20 years. Dr. Larrick received his M.D. and Ph.D. degrees from Duke University School of Medicine, Durham, NC. After housestaff training in the Department of Medicine at Stanford University School of Medicine, he completed a post-doctoral fellowship in the Stanford Cancer Biology Research Labs with Professor Henry S. Kaplan. In 1982, he joined Cetus Immune Research Labs, Palo Alto, CA, where he became Director of Research in 1986. While at Cetus he pioneered the use of PCR for the construction of recombinant antibodies. In 1988 he moved to Genelabs Incorporated, Redwood City, CA, as Director of Exploratory Research. In 1991, Dr. Larrick founded the Palo Alto Institute of Molecular Medicine, a non-profit research institute situated near Stanford University.

Fact sheet

Products & services

Similar companies nearby